2013 Financial Year
21 February 2013

This presentation has been prepared by Nuplex Industries Limited. The material that follows contains general background information about Nuplex’s activities as at the date of the presentation 21 February 2013.
The information in this presentation is not an offer or recommendation to purchase or subscribe for securities in Nuplex or to retain any securities currently held. It does not take into account the potential and current individual investment objectives or the financial situation of investors.
Actual results may vary materially either positively or negatively from any forecasts in this presentation. Before making or disposing of any investment in Nuplex securities, investors should consider the appropriateness of that investment in light of their individual investment objectives and financial situation, and seek their own professional advice.
All currencies are in NZD unless stated otherwise.
1

Making progress towards our goal of zero harm
Lost time injury frequency rate per million employee hours worked
15
10
5
0
0
FY04 FY05 FY06 FY07 FY08 FY09 FY10 FY11 FY12 1H13
Total reportable injury frequency rate per million employee hours worked
30
20
10.2
10
0
FY04 FY05 FY06 FY07 FY08 FY09 FY10 FY11 FY12 1H13
2

Sales revenue
$828.7m
EBITDA 1
$57.6m
up 11.0% steady
NPAT 2 after significant items
$11.5m
down 52.3%
NPAT before significant items
$24.5m
down 9.6%
Earnings per share
5.8 cents down from 12.3 cents
Dividend per share
10 cents unchanged
Return of funds employed 3
9.8% down from 12.1%
Working capital to sales ratio
14.8% down from 16.5%
1 Earnings before interest, tax, depreciation and amortisation
2 Net profit after tax attributable to equity holders of the parent company
3 As defined by earnings before interest, tax and unusual items divided by average funds
All figures are in NZD unless otherwise stated
3

Taking action to improve returns on funds employed
Existing operations steady despite significant weakness in Australia and volatility in Europe in November/ December
• Resins segment excluding acquisitions
– Volume growth due to Asia and Americas offsetting ANZ and Europe
– Unit margins up 3.4% 1
Strengthening Nuplex by reducing costs
• Restructuring Australia and New Zealand to adapt to changing markets
• Executing NuLEAP I - delivered $6m during 1H13, on track to deliver program target of
$30m net benefits by the end of the FY13
• Investing in NuLEAP II - procurement initiative to deliver $5.3m in 2H13, $12m in FY14
Acquisitions successfully integrated – delivering in line with forecast in FY13 and acquisition criteria
• Viverso on track to deliver EBITDA of €12m
• Nuplex Masterbatch on track to deliver EBITDA of A$5m
1. Defined as a unit margin as a percentage of sales = sales revenue minus raw material costs divided by tonnage
All figures in NZD unless otherwise stated
4

EBITDA
• Supported by Viverso and Masterbatch contributions
• Impacted by
‒ ANZ restructure and procurement costs
‒ Ongoing strength of the New Zealand dollar
1H13 vs 1H12 1
Geographic diversity supported existing operations
• Weakness in Australia and end-of-year slow down in
EMEA largely mitigated by growth in Asia and
Americas
Sales revenue
EBITDA
EBITDA before restructure and procurement costs
NPAT impacted by write downs
• $13m in significant items including
‒ $5.8m write down of obsolete equipment in ANZ
‒ $5.5m write down of Fibrelogic investment
NPAT after significant items
Interim dividend maintained at 10 cents per share
• Strong cash flows reflecting margin management and tight cost control
• Declared in context of the outlook for the full year
1 See slide 25 for underlying data, 2. Excluding acquisitions
All figures in NZD unless otherwise stated
NPAT before significant items and restructure and procurement costs
% growth constant FX
Group
14.8%
4.2%
14.8%
(50.3)%
8.9%
Existing operations 2
(2.7)%
(14.5)%
(5.3)%
(53.1)%
2.6%
5

Solid EBITDA despite continued challenging market conditions particularly in
Australian coating resins business
$57.3m
3.2
(2.1)
$57.6m
0.5
(3.1)* 1.5*
(7.3)
(6.1) 8.6
(4.5)* 9.7
*
1H12
EBITDA
Resins volume *
Unit margin *
Specialties
Cost inflation
- wages, utilities etc
Other fixed costs
NuLEAP
- benefit increase from
1H12 to
1H13
Restructure and procurement costs at
1H12 FX rates
Viverso at 1H12
FX rates
Masterbatch at
1H12 FX rates
FX
Excluding the impact of NuLEAP initiatives and acquisitions
1H13
EBITDA
6

Restructuring to improve returns
7 sites
Pre-restructure
Reducing capacity to meet future demand
• Closing 1 site in New Zealand,
2 in Australia
• Expected restructure costs $9.6m
1
• Closures to occur 1 st half FY14
Investing to improve efficiency and further reduce costs
• Investing $13m to improve customer responsiveness and efficiency 4 sites
Benefits to flow from 2H13
• 2H13: $0.5m in cost savings
• FY14: $3.7m cost savings, 0.5 cents EPS uplift
• FY15: fully realised $5.6m cost savings,
2 cents EPS uplift
1 Timing of expected restructure costs 1H13 $2.8m, 2H13 $4.0m, FY14 $2.8
All figures in NZD unless otherwise stated
Post-restructure
7

Improving procurement and delivering significant cost savings
NuLEAP I on track to deliver $30m net benefits by end FY13
• 1H13 $6m realised
‒ 40% procurement, 40% sales, 20% operating costs
‒ Resins segment unit margins up 3.4%
NuLEAP II transformative procurement initiative
• Adopting a center-led approach supported by regional hubs
• Invested $3.2m in 1H13
• Benefits from this initiative to flow from
2H13
‒ $5.3m in 2H13
‒ $12m in FY14
All figures in NZD unless otherwise stated
Decentralised
Country procurement managers
Site buyer
Center-led
Global category managers
Regional procurement managers
Implementing
• Strategic sourcing processes
• Category management disciplines
8

Specialties
Resins
EBITDA including Viverso $45.2m down 3.6% (up 0.6% constant FX)
• Includes $6m in costs to restructure ANZ ($2.8m) and upfront costs of procurement initiative ($3.2m)
EBITDA excluding Viverso, restructure and procurement costs $42.4m down 8.5%
(down 6.4% constant FX)
Europe, Middle East & Africa (EMEA)
• 2.5% volume growth ex Viverso
– Growth in powder resins
– Decorative, Marine & Protective and Auto OEM resins segments weaker
• EBITDA ex Viverso €9.2m down 3.2%
– Earlier than usual end-of-year slowdown
– Increased R&D costs, contribution to employee fund
Viverso
• Integration complete with successful transition of complex IT systems
• 1H13 performance in line with management expectations
• On track to deliver €12m in FY13
• Focus now on operational improvement and leveraging product portfolio
Americas
• 3.7% volume growth
– Growth in higher margin
High End Metal coatings
• EBITDA US$7.3m up 40.4%
• Tight cost control
• Contribution from sale of
Viverso products
All figures in NZD unless otherwise stated
Asia
• 10.3% volume growth
– Growth in China (Auto OEM, Vehicle Refinish),
Indonesia (Decorative) & Malaysia (Regional exports)
• EBITDA US$12.1m up 16.3%
• Contribution from sale of Viverso products
• Vietnam impacted by slowdown in housing market. New capacity still expected to be filled in 4 years
Australia & New Zealand
• Volumes down 11.4%
• EBITDA A$3.8m down 56.8% after A$1.6m restructure costs
• Cyclical low construction activity impacted demand
• Importation of finished goods continued to impact manufacturing customers
• Margin management and cost control mitigated some of volume impact
9

EBITDA $12.4m up 19.2% (up 20.2% constant FX)
Specialties
Agency and distribution
Defensive sectors growing
• Food and nutrition growing due to chocolate
• Pharmaceutical and healthcare
• Ongoing weakness in plastics, foam, paints and coatings
Nuplex Masterbatch
Integration/restructure complete
• 2 sites closed
• Improved margins
• Enhanced customer offering: expanded colour range, black and performance additives
Delivering in line with acquisition base case
• On track to deliver A$5m
EBITDA in FY13
Resins
All figures in NZD unless otherwise stated
10

NZ$ million
Sales
EBITDA
Depreciation and amortisation
EBIT
Net financing costs
Share of associates
Minority interests (non controlling interests)
Tax on operating profits
Underlying NPAT
Write downs
Legal provisions
Loss on sale of Plaster Systems NZ
Acquisition related costs
Income tax credit on non-operating items
NPAT attributable to equity holders of parent company
(7.7)
24.5
(13.6)
(0.3)
(0.7)
(0.8)
2.4
11.5
1H13
828.7
57.6
(16.0)
41.6
(9.1)
0.9
(1.2)
(9.2)
27.1
-
(0.4)
-
(2.6)
-
24.1
1H12
746.4
57.3
(12.2)
45.1
(6.5)
(1.3)
(1.0)
% change
11.0%
0.5%
30.7%
(7.7)%
38.6%
-
21.8%
(16.5)%
(9.6)%
(17.8)%
-
-
(71.5)%
-
(52.3)%
12

NZ$ million
EBITDA
Financing costs
Provisions/other
Loss on business disposal
Movement in working capital
Tax paid
Dividends from associates
Cash-flow from operations before significant items
Cash flow from significant items
Cash-flow from operations
Capital expenditure less proceeds of disposal
Cash flow
Dividends paid
Free cash flow
1H13
57.6
(9.1)
1.8
0.6
11.2
(14.3)
1.3
49.2
(1.7)
47.5
(18.8)
28.6
(18.7)
9.9
1H12
57.3
(6.5)
(2.0)
-
(9.9)
(15.9)
1.3
24.3
(3.0)
21.3
(13.0)
8.3
(22.3)
(14.1)
$ change
0.3
(2.6)
3.8
0.6
21.1
1.6
24.9
-
1.3
26.2
(5.8)
20.3
3.6
24
13

Working capital to sales ratio 14.8%
Stay in business capex
• 1H13: $12.2m, equivalent to 95.4% of depreciation
‒ $2.9m global ERP project
‒ $2.3m new reactors at Botany, Wacol, and East St.Louis
‒ $1.2m Suzhou Technical Centre
• FY13: expected to be 120% of depreciation
Working capital as a percentage of 12-month rolling sales
20%
18%
16%
Target range 15-17%
16.5
15.8
14.8
14%
12%
10%
Organic growth capex
• 1H13: $6.7m
‒ China new site $4.8m
• FY13 forecast approximately $20m
• FY14 forecast $25 to $30m
8%
6%
4%
2%
All figures in NZD unless otherwise stated
0%
Dec 08 Jun 09 Dec 09 Jun 10 Dec 10 Jun 11 Dec 11 June 12 Dec 12
14

$209m net debt as at 31 December 2012
• Largely unchanged from $220m as at
30 June 2012
Average cost of debt 6.6%
Completed US$105m US private placement funding
• 7 year term, mature 2019
• Coupon rate 6.125%
• Settled 31 July 2012
NZ$52.6m of Capital Notes redeemed
September 2012
Note: All figures are in NZD unless otherwise stated
Net debt to net debt plus equity ratio
60%
50%
40%
30%
Target range
20-35%
27.4%
20%
10%
0%
Dec 07 Dec 08 Dec 09 Dec 10 Dec 11 Dec 12
15

Our ambition
Our strategy
FY2013
Execution
To be the leading, trusted independent polymer resins manufacturer globally, and leading agency and distribution business in ANZ
To achieve superior shareholder returns by delivering high quality products to our customers through pursuing operational excellence, innovation and building market leading positions
Strengthening through operational excellence Growing through building market leading positions
Safety
• Build a culture of
‘zero harm’
• Implementing global common standards relating to processes and policies
• Health &
Wellbeing program in ANZ
People
• Engage and leverage One
Global Team
• Introduce global
Overlay Teams to leverage products, R&D and procurement across the group
• Global Senior
Management
Conference
• Employee survey
• Nuplex
Leadership
Academy: online development program
NuLEAP
• Improve the way we work through rigorous improvement programs
• NuLEAP I
− Final phase of execution
• NuLEAP II
− Planning
− Procurement initiative
• Restructure of
Australia and
New Zealand
Emerging markets
• Profitably expand capacity and presence in emerging markets
• China: 3 rd site progressing
US$35m
• Indonesia: capacity expansion
US$5.4m
• Russia: finalising JV
• Thailand: capacity expansion
R&D
• Grow market share through innovative products
• Pursue market development opportunities
• Leverage technologies across global platform
• Preparing for launch of new products at
European
Coatings Show in March 2013
• Succession planning for
R&D personnel
Strategic acquisitions
• Consider acquisitions that
− Strengthen leading market
& technology positions
− Leverage capabilities
− Meet disciplined criteria
• Consolidation of recent acquisitions
− Integration
− Improving operational performance
− Leveraging benefits of product portfolio
17

Sales by region 1
%
100%
China, Changshu
• Investing US$35m
• Double capacity in China
• Delayed 6 months
• Commissioning now expected end FY14
Americas
Asia
EMEA
100%
9
12
21
100%
9
16
31
9
20
34
Indonesia, Surabaya
• Investing US$5.4m
• Expanding capacity and adding new technology
• Commissioning expected end FY14
Thailand, Bangkok
• Joint venture
• Investing US$1.5m
• Expanding powder capacity 40%
• Funded from cash within JV
ANZ
58
FY09
44
FY12
37
FY15
Russia, Belgorod
• Joint venture negotiations nearing completion
• Expect to be operating 4 th quarter FY13
• Initial investment of €8m in existing plant
& equipment and working capital
– Nuplex equity investment €2.5m
• Working towards starting construction of new site in 2014
– estimated investment €20 million,
Nuplex share 50% expected
1. FY09 sales retranslated at FY12 exchange rates (base case 2 )
2. Forecast subject to unforeseen circumstances and economic uncertainty
18

ANZ
• New Zealand: in recovery mode
• Australia: bouncing along the bottom?
Asia
• China: signs of an upturn in China
• SE Asia: growing steadily
Europe
• While activity is volatile, demand steady
Americas
• Steady growth
EBITDA now expected to be between $135m and $140m
• Assumes similar market conditions in 2H13
• Is based on 1H13 average exchange rates
• Acquisitions on track to deliver EBITDA targets; Viverso €12m, Nuplex Masterbatch $5m
• NuLEAP on track to deliver at least $13m
• Procurement initiative to deliver benefits of $5.3m in the second half
• ANZ restructure costs of $6.8m
Note: All figures are in NZD unless otherwise stated
19

FOR FURTHER DETAILS:
Emery Severin
Chief Executive Officer

+61 2 8036 0902
 emery.severin@nuplex.com
Josie Ashton
Investor Relations
 +61 2 8036 0906 or

+61 416 205 234
 josie.ashton@nuplex.com